Humans of AI3SD: Dr Mark Warne

Pauli, Michelle and Warne, Mark , Kanza, Samantha, Frey, Jeremy G. and Niranjan, Mahesan (eds.) (2021) Humans of AI3SD: Dr Mark Warne (Humans-of-AI3SD, 18) University of Southampton 8pp. (doi:10.5258/SOTON/AI3SD0183).

Record type: Monograph (Project Report)

Abstract

This interview forms part of our Humans of AI3SD Series

Text

Humans_of_AI3SD_Interview-18_MW - Version of Record

Available under License Creative Commons Attribution.

Download (269kB)

More information

Published date: 2021

Additional Information: Mark Warne, was appointed as Chief Executive Officer of DeepMatter Group plc on the 2 July 2018. Mark, who joined DeepMatter as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and International life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/2017 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a non-executive director on the boards of Open Orphan plc and Ixico plc.

Keywords: AI3SD, Interview

Learn more about Vision, Learning and Control research Learn more about Institute for Life Sciences research